NGEN
NervGen Pharma Corp.
1.80$
+1.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +1,745.9% | -0.5% | +0.6% | +0.2% | -0.3% | +2.6% | -3.3% | +4.7% | +0.1% | +0.6% | -0.3% | +5.8% | -18.3% | +3.1% | +27.9% | +201.0% | +0.6% | +0.1% | +0.9% | +0.6% | +4.4% | +5.8% | -0.7% | -60.9% | -2.6% | +8.0% | -12.2% | +1.1% | -0.3% | -314.4% | – | +1.0% | – | |
| – | – | -197.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -147.3% | – | – | |
| – | – | -48.4% | +3,467.6% | +69.8% | +336.5% | -58.1% | +86.9% | +10.9% | -42.0% | +0.0% | -34.0% | +365.8% | -77.5% | +112.3% | +1.8% | +25.7% | +79.3% | +32.0% | -33.6% | +59.8% | -40.1% | -49.9% | -45.4% | +222.4% | +11.6% | +27.7% | +16.3% | +3.9% | -31.5% | -13.4% | +63.7% | +47.8% | -24.8% | +64.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +30.4% | +30.2% | -54.1% | +62.2% | -4.7% | +61.4% | – | |
| – | -336.0% | – | +686.8% | +49.0% | +299.4% | -48.1% | +50.6% | +26.2% | -38.0% | +32.1% | -16.6% | +117.1% | -49.7% | +24.1% | +5.4% | +13.0% | +52.0% | +25.9% | -22.9% | +38.1% | -30.0% | +1.1% | -28.8% | +43.6% | +2.1% | +21.1% | +20.4% | -5.8% | -11.8% | +8.4% | -5.0% | +90.3% | -34.9% | +63.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -520.7% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -125.1% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.